Latest Headlines
-
Labcorp To Acquire Select Parkview Health Laboratory Outreach Assets
11/13/2025
Labcorp a global leader of innovative and comprehensive laboratory services, and Parkview Health, one of the fastest growing health systems in the Midwest, today announced a strategic agreement for Labcorp to acquire select assets of the health system’s outreach laboratory services that provides high-quality testing across Indiana and northwest Ohio.
-
Thermo Fisher Scientific Receives 510(k) Clearance In The United States For EXENT System* To Aid In The Diagnosis Of Multiple Myeloma
11/12/2025
Thermo Fisher Scientific Inc. the world leader in serving science, today announced 510(k) clearance of the EXENT Analyser and Immunoglobulin Isotypes (GAM) Assay**, a first-of-its-kind automated platform for clinical laboratories.
-
Microbix Partners With SEKISUI Diagnostics To Support COVID/Flu Tests
11/12/2025
Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and SEKISUI Diagnostics, LLC (SEKISUI), a global manufacturer of innovative diagnostic tests, reagents, diagnostic systems, and raw materials, announce that Microbix external third-party quality assessment products (REDx™FLOQ® QAPs®) will be used to support SEKISUI’s U.S. commercialization of the molecular point-of-care assay for diagnosis of COVID/Flu A/Flu B using the Metrix® platform from Aptitude Medical Systems, Inc. (Aptitude).
-
Mainz Biomed Showcases Innovative Cancer Detection Solutions At MEDICA 2025
11/12/2025
Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in MEDICA 2025, one of the world’s leading healthcare trade shows, taking place from 17–20 November, 2025, in Düsseldorf, Germany.
-
Pillar Biosciences Enables Rapid, Localized Tumor Profiling Of Lymphoid Malignancies With Launch Of New Kitted NGS Panel
11/12/2025
Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the launch of oncoReveal® Lymphoid, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories to perform rapid tumor profiling of lymphoid malignancies.
-
EXoPERT Joins JLABS TMC, Johnson & Johnson's Global Incubator Network
11/12/2025
EXoPERT, a biotechnology company pioneering AI-powered exosome-based liquid biopsy diagnostics for multi-cancer early detection, is excited to announce that it has joined Johnson & Johnson's global incubator network, JLABS, as a resident of JLABS TMC.
-
GenomOncology Partners With Glioblastoma Foundation To Accelerate Precision Glioblastoma Brain Cancer Treatment
11/11/2025
GenomOncology today announced a strategic partnership with the Glioblastoma Foundation to transform genomic testing for the nation's most aggressive brain cancer, glioblastoma.
-
Guardant Health Expands Tissue-Free Reveal Test To Include Late-Stage Therapy Response Monitoring
11/10/2025
Guardant Health, Inc. a leading precision oncology company, today announced the expansion of its Guardant Reveal blood test to include late-stage therapy response monitoring for patients with solid tumors.
-
Geneseeq Receives NMPA Approval For PanTRKare™ - China's First NGS-Based Pan-Solid Tumor Companion Diagnostic Kit For NTRK Gene Fusions
11/10/2025
Geneseeq Technology Inc., a global precision oncology company, today announced its PanTRKare™NTRK1/NTRK2/NTRK3 Gene Fusion Detection Kit has received marketing authorization from China's National Medical Products Administration (NMPA).
-
Optimizing Sample Traceability: Speed And Precision Via Laser Marking Technology
11/7/2025
Earlier this year, AFYS3G announced the launch of the Information Marking System Lambda768. A next-generation laser marking solution engineered to redefine efficiency in sample identification.